Literature DB >> 22834568

Transdermal granisetron: a guide to its use in preventing nausea and vomiting induced by chemotherapy.

Gillian M Keating1, Sean T Duggan, Monique P Curran.   

Abstract

Transdermal granisetron (Sancuso®) is effective in the prevention of nausea and vomiting in patients with cancer who are receiving moderately or highly emetogenic chemotherapy for 3-5 days. Transdermal granisetron is noninferior to oral granisetron in this indication, and is generally well tolerated in this indication. Thus, transdermal granisetron provides a convenient option for the prevention of chemotherapy-induced nausea and vomiting, with the potential to improve patient compliance.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22834568     DOI： 10.2165/11209440-000000000-00000

Source DB:  PubMed          Journal:  CNS Drugs        ISSN： 1172-7047            Impact factor:   5.749


  8 in total

Review 1.  Transdermal delivery of drugs for urologic applications: basic principles and applications.

Authors:  Victor W Nitti; Steven Sanders; David R Staskin; Roger R Dmochowski; Peter K Sand; Scott MacDiarmid; Howard I Maibach
Journal:  Urology       Date:  2006-04       Impact factor: 2.649

Review 2.  Chemotherapy-induced nausea and vomiting.

Authors:  Paul J Hesketh
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245

Review 3.  Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 4.  Transdermal granisetron.

Authors:  Sean T Duggan; Monique P Curran
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 5.  Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments.

Authors:  Rudolph M Navari
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 6.  Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy.

Authors:  Y E Yarker; D McTavish
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

Review 7.  Chemotherapy-induced nausea and vomiting.

Authors:  Lisa Lohr
Journal:  Cancer J       Date:  2008 Mar-Apr       Impact factor: 3.360

8.  Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study.

Authors:  Ralph V Boccia; Lucio N Gordan; Gemma Clark; Julian D Howell; Steven M Grunberg
Journal:  Support Care Cancer       Date:  2010-09-12       Impact factor: 3.603
  8 in total
  4 in total

1.  Granisetron transdermal system improves refractory nausea and vomiting in gastroparesis.

Authors:  Kellie Simmons; Henry P Parkman
Journal:  Dig Dis Sci       Date:  2014-03-11       Impact factor: 3.199

2.  A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients.

Authors:  Jeong Eun Kim; Yong Sang Hong; Jae-Lyun Lee; Kyu-Pyo Kim; Seong Joon Park; Sun Jin Sym; Dong Bok Shin; Jeeyun Lee; Young Suk Park; Jin Seok Ahn; Tae Won Kim
Journal:  Support Care Cancer       Date:  2014-12-03       Impact factor: 3.603

3.  Granisetron Transdermal System for Treatment of Symptoms of Gastroparesis: A Prescription Registry Study.

Authors:  Deena Midani; Henry P Parkman
Journal:  J Neurogastroenterol Motil       Date:  2016-10-30       Impact factor: 4.924

Review 4.  Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant-palonosetron combination.

Authors:  Piotr K Janicki
Journal:  Ther Clin Risk Manag       Date:  2016-05-02       Impact factor: 2.423
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.